Literature DB >> 15750158

18F-CPFPX PET identifies changes in cerebral A1 adenosine receptor density caused by glioma invasion.

Andreas Bauer1, Karl-Josef Langen, Hans Bidmon, Marcus H Holschbach, Simone Weber, Ray A Olsson, Heinz H Coenen, Karl Zilles.   

Abstract

UNLABELLED: Adenosine plays a critical role in both tumor proliferation and the cerebral response to tumor invasion. We used 8-cyclopentyl-3-(3-18F-fluoropropyl)-1-propylxanthine (18F-CPFPX) PET to investigate A1 adenosine receptor (A1AR) density as a potential indicator of the local cerebral response to glioma invasion.
METHODS: A1AR density in F98 glioma-bearing rats was examined by 18F-CPFPX and 3H-CPFPX using PET, quantitative in vitro and ex vivo double-label receptor autoradiography, and immunohistochemical analyses.
RESULTS: For all imaging modalities, A1AR signal intensity was increased in a zone surrounding experimental tumors (136%-146% that in control tissue) (P < 0.01). Immunostaining identified activated astrocytes as the main origin of peritumoral A1AR upregulation. The results of a pilot 18F-CPFPX PET study on a patient with recurrent glioblastoma multiforme confirmed increases in A1AR density in the immediate vicinity of the tumor.
CONCLUSION: 18F-CPFPX PET is suitable for the detection of peritumoral changes in A1AR density. Molecular imaging with 18F-CPFPX PET may open novel possibilities for gaining experimental and clinical insights into the cerebral response to tumor invasion.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15750158

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  13 in total

1.  Test-retest stability of cerebral A1 adenosine receptor quantification using [18F]CPFPX and PET.

Authors:  David Elmenhorst; Philipp T Meyer; Andreas Matusch; Oliver H Winz; Karl Zilles; Andreas Bauer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-01-23       Impact factor: 9.236

Review 2.  Molecular imaging of brain tumors: a bridge between clinical and molecular medicine?

Authors:  B J Schaller; M Modo; M Buchfelder
Journal:  Mol Imaging Biol       Date:  2007 Mar-Apr       Impact factor: 3.488

Review 3.  Adenosine receptors as therapeutic targets.

Authors:  Kenneth A Jacobson; Zhan-Guo Gao
Journal:  Nat Rev Drug Discov       Date:  2006-03       Impact factor: 84.694

4.  Invited Lectures : Overviews Purinergic signalling: past, present and future.

Authors: 
Journal:  Purinergic Signal       Date:  2006-05-15       Impact factor: 3.765

Review 5.  Introduction to adenosine receptors as therapeutic targets.

Authors:  Kenneth A Jacobson
Journal:  Handb Exp Pharmacol       Date:  2009

6.  Synthesis and characterization of [76Br]-labeled high-affinity A3 adenosine receptor ligands for positron emission tomography.

Authors:  Dale O Kiesewetter; Lixin Lang; Ying Ma; Abesh Kumar Bhattacharjee; Zhan-Guo Gao; Bhalchandra V Joshi; Artem Melman; Sonia de Castro; Kenneth A Jacobson
Journal:  Nucl Med Biol       Date:  2009-01       Impact factor: 2.408

Review 7.  Mechanisms of induction of adenosine receptor genes and its functional significance.

Authors:  Cynthia St Hilaire; Shannon H Carroll; Hongjie Chen; Katya Ravid
Journal:  J Cell Physiol       Date:  2009-01       Impact factor: 6.384

8.  Differential Expression of Adenosine P1 Receptor ADORA1 and ADORA2A Associated with Glioma Development and Tumor-Associated Epilepsy.

Authors:  Jun Huang; Ming-Na Chen; Juan Du; Hao Liu; Yu-Jiao He; Guo-Liang Li; Shu-Yu Li; Wei-Ping Liu; Xiao-Yan Long
Journal:  Neurochem Res       Date:  2016-04-02       Impact factor: 3.996

9.  Biodistribution and radiation dosimetry of the A1 adenosine receptor ligand 18F-CPFPX determined from human whole-body PET.

Authors:  Hans Herzog; David Elmenhorst; Oliver Winz; Andreas Bauer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-03-29       Impact factor: 9.236

10.  Association of adenosine receptor gene polymorphisms and in vivo adenosine A1 receptor binding in the human brain.

Authors:  Christa Hohoff; Valentina Garibotto; David Elmenhorst; Anna Baffa; Tina Kroll; Alana Hoffmann; Kathrin Schwarte; Weiqi Zhang; Volker Arolt; Jürgen Deckert; Andreas Bauer
Journal:  Neuropsychopharmacology       Date:  2014-06-19       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.